MPM Capital
MPM Capital is a biotechnology investment firm that invests in early-stage companies to develop therapeutic technologies in oncology.
Business Model:
Revenue: $4.5M
Employees: 11-50
Rankings
Industries / Tags:
Detailed MPM Capital Information
Geographic Data
Address: 450 Kendall Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Twitter
Linkedin
Crunchbase
Metrics
966,501Website Global Rank
28,580Website Monthly Traffic
Twitter Followers
Description
MPM Capital is a healthcare investment firm that invests in early-stage companies developing therapeutic technologies in oncology. They invest in life sciences companies that seek to cure diseases by translating science into clinical outcomes. They prefer to invest in the biotechnology, healthcare, and life sciences sectors.
Contact Phone:
+16174259200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2015 | 23andMe | Series E | 115M |
| 5/2003 | Cellerant Therapeutics | Series A | 10M |
| 6/2005 | Verus Pharmaceuticals | Series A | 0 |
| 6/2003 | CryoCor | Series C | 27.5M |
| 5/2001 | SenoRx | Venture Round | 19M |
| 9/2000 | CryoCor | Series A | 7M |
| 2/2006 | NeoRX Corporation (Poniard Pharmaceuticals) | Post-IPO Equity | 65M |
| 1/2011 | 23andMe | Series C | 9M |
| 11/2002 | Critical Therapeutics,Inc. | Series A | 10M |
| 9/2008 | Valeritas | Series A | 50M |
| 10/1999 | Pharmasset | Series B | 3.9M |
| 9/2008 | Innovative Spinal Technologies | Series C | 18M |
| 1/2006 | Xoft | Series C | 0 |
| 10/2005 | Alinea Pharmaceuticals | Series A | 45M |
| 7/2004 | Arriva Pharmaceuticals | Series D | - |
| 11/2004 | Neosil | Series A | 32M |
| 5/2005 | Oxagen | Series B | 0 |
| 3/2016 | Tizona Therapeutics | Series B | 43M |
| 1/2017 | Maverick Therapeutics | Venture Round | 125M |
| 1/2013 | Aratana Therapeutics | Series C | 0 |
| 3/2006 | Helicos BioSciences | Series B | 40M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 3/2017 | Semma Therapeutics | Venture Round | - |
| 8/2004 | Ceregene | Series B | 32M |
| 2/2006 | ARYx Therapeutics | Series E | 30.4M |
| 11/2010 | Verastem Oncology | Series A | 16M |
| 6/2016 | arGEN-X | Post-IPO Equity | 34.1M |
| 3/2015 | Semma Therapeutics | Series A | 44M |
| 7/2005 | Xanodyne | Series A | 170M |
| 1/2004 | Amphora Discovery | Series B | 12.9M |
| 9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
| 7/2012 | Chiasma | Series D | 38.5M |
| 10/2013 | Mitobridge | Series A | 0 |
| 6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
| 2/2021 | Orna Therapeutics | Series A | 0 |
| 8/2020 | Trishula Therapeutics | Funding Round | - |
| 4/2016 | Twentyeight-Seven Therapeutics | Series A | - |
| 12/2002 | Amphora Discovery | Series B | 12.5M |
| 4/2013 | Radius Health | Private Equity Round | 43M |
| 5/2008 | SAI Life Sciences | Private Equity Round | 20M |
| 1/2006 | Archus Orthopedics | Series C | 35M |
| 4/2016 | Harpoon Therapeutics | Series A | 15M |
| 5/2012 | NeoVista | Venture Round | 6M |
| 11/2011 | Meritage Pharma | Venture Round | 6.5M |
| 7/2005 | Integrated Diagnostics | Series A | - |
| 7/2009 | iPierian | Venture Round | 11.5M |
| 8/2008 | Peplin | Private Equity Round | 24M |
| 5/2003 | Acorda Therapeutics | Series B | 55.3M |
| 12/2018 | Entrada Therapeutics | Series A | 59M |
| 11/2006 | Elixir Pharmaceuticals | Series C | 0 |
| 11/2017 | Semma Therapeutics | Series B | 0 |
| 10/2003 | Elixir Pharmaceuticals | Series B | 40.5M |
| 10/2009 | Xanodyne | Venture Round | 0 |
| 6/2005 | Amphora Discovery | Series D | 9.6M |
| 1/2020 | BioIntervene | Series A | 30M |
| 11/2004 | Accelerator Corp. | Venture Round | 0 |
| 2/2008 | Epizyme | Series A | - |
| 3/2020 | ElevateBio | Series B | 170M |
| 7/2002 | ARYx Therapeutics | Series C | 25M |
| 7/2008 | Peptimmune | Series D | 8.9M |
| 4/2002 | IntraLuminal Therapeutics | Venture Round | 20M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 6/2002 | MacroGenics | Venture Round | 12.6M |
| 6/2004 | ARYx Therapeutics | Series D | 55M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 2/2015 | Chiasma | Series E | 70M |
| 11/2020 | Umoja Biopharma | Series A | 53M |
| 9/2019 | Repare Therapeutics | Series B | 82.5M |
| 2/2000 | DoubleTwist | Series D | 37M |
| 7/2005 | Affymax | Series D | 60M |
| 8/2022 | Orna Therapeutics | Series B | 0 |
| 11/2006 | Chiasma | Series C | 44M |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 8/2005 | Innovative Spinal Technologies | Series B | 39M |
| 6/2019 | Frontier Medicines | Series A | 67M |
| 6/2012 | Motus Therapeutics | Series B | 25M |
| 3/2020 | ReCode Therapeutics | Series A | 0 |
| 1/2002 | BioXell | Series A | 19.7M |
| 5/2005 | Cellerant Therapeutics | Series B | 16M |
| 4/2020 | ITeos Therapeutics | Series B | 0 |
| 9/2011 | Valeritas | Series C | 150M |
| 11/2008 | Pacira Pharmaceuticals | Series A | 85M |
| 7/2011 | Verastem Oncology | Series B | 32M |
| 12/2016 | TCR2 | Series A | 44.5M |
| 9/2010 | EnteroMedics | Post-IPO Equity | 6.3M |
| 3/2010 | Motus Therapeutics | Series A | 21M |
| 4/2007 | Radius Health | Series B | 57.5M |
| 1/2020 | Orna Therapeutics | Seed Round | 20M |
| 1/2011 | Aratana Therapeutics | Series A | 0 |
| 9/2007 | JapanBridge | Series A | 6.5M |
| 4/2019 | Dyne Therapeutics | Series A | 50M |
| 12/2006 | NBI Development | Seed Round | 5.5M |
| 3/2015 | Clinical Ink | Venture Round | 20M |
| 3/2008 | EKR Therapeutics | Series D | 50M |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 3/2006 | Neuromed Pharmaceuticals | Series D | 0 |
| 4/2015 | True North Therapeutics | Series B | 35M |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 12/2002 | Intracel Holdings Corporation | Series B | 16M |
| 4/2011 | Conatus Pharmaceuticals | Series B | 7.5M |
| 9/2019 | Amphivena Therapeutics | Series C | 0 |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
| 6/2006 | VLST Corporation | Series B | 55M |
| 10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
| 10/2003 | Cotherix | Series C | 55M |
| 6/2017 | Repare Therapeutics | Series A | 68M |
| 2/2006 | Amphora Discovery | Series E | 4.4M |
| 9/2011 | Theraclone Sciences | Series B | 10.6M |
| 7/2016 | Oncorus | Series A | 57M |
| 12/2012 | 23andMe | Series D | 50M |
| 1/2008 | PrimeraDx (Primera Biosystems) | Series B | 21M |
| 3/2008 | TriVascular | Series A | 65M |
| 3/2009 | Surface Logix | Series E | 15M |
| 7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
| 11/2012 | Motus Therapeutics | Series B | 8M |
| 3/2015 | Vascular Pharmaceuticals | Series A | 9M |
| 9/2004 | EndoGastric Solutions | Series B | 12M |
| 5/2023 | ReNAgade Therapeutics | Series A | 0 |
| 3/2013 | CoStim Pharmaceuticals | Series A | 22M |
| 11/2019 | Werewolf Therapeutics | Series A | 0 |
| 8/2010 | EndoGastric Solutions | Series F | 0 |
| 6/2009 | EndoGastric Solutions | Venture Round | 3.8M |
| 8/2001 | Eyetech Pharmaceuticals | Series C | 108.5M |
| 3/2001 | Pharmasset | Series C | 7.4M |
| 10/2014 | Atopix Therapeutics | Series A | 0 |
| 11/2011 | Verastem Oncology | Series C | 20M |
| 10/2005 | Cerimon Pharmaceuticals | Series A | 70M |
| 6/2003 | Xoft | Series B | 0 |
| 10/2014 | Raze Therapeutics | Series A | 24M |
| 4/2003 | Epigenomics | Series C | 22.5M |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 3/2005 | Humanigen | Series B | 20M |
| 6/2003 | EndoGastric Solutions | Series A | 5M |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 1/2009 | TaiGen Biotechnology | Series C | 0 |
| 3/2004 | TaiGen Biotechnology | Series B | 0 |
| 7/2009 | PharmAthene | Post-IPO Secondary | 19.3M |
| 6/2007 | Ceregene | Series C | 0 |
| 7/2011 | Radius Health | Series C | 66M |
| 5/2017 | Harpoon Therapeutics | Series B | 45M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 12/2005 | Hypnion | Series B | 0 |
| 7/2014 | Valeritas | Series D | 45M |
| 4/1999 | Omrix Biopharmaceuticals | Venture Round | 20M |
| 11/2019 | SiO2 Materials Science | Venture Round | - |
| 8/2004 | Pharmasset | Series D | 40M |
| 9/2022 | Photys | Series A | 0 |
| 8/2022 | Aktis Oncology | Series A | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 10/2021 | Protego Biopharma | Series A | 0 |
| 6/2020 | Cullinan Oncology | Series B | 98.5M |
| 10/2017 | Cullinan Oncology | Series A | 150M |
| 6/2018 | ITeos Therapeutics | Series B | 0 |
| 8/2003 | Archus Orthopedics | Series B | 18M |
| 2/2012 | Helicos BioSciences | Series A | 27M |
| 1/2004 | CGI Pharmaceuticals | Series C | 22.3M |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 3/2021 | Aktis Oncology | Series A | 72M |
| 5/2006 | MacroGenics | Series C | 45M |
| 9/2001 | MacroGenics | Series A | 13.5M |
| 4/2007 | Cellerant Therapeutics | Series B | 0 |
| 6/2004 | Idun Pharmaceuticals | Venture Round | 0 |
| 4/2001 | Genteric | Series B | 22M |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 12/2006 | Nevro | Seed Round | 5.5M |
| 9/2008 | Nevro | Series A | 21.8M |
| 4/2018 | Tetherex | Series B | 50M |
| 1/2010 | Alnara Pharmaceuticals | Series B | 35M |
| 11/2003 | Neuromed Pharmaceuticals | Series C | 32M |
| 8/2007 | Neuromed Pharmaceuticals | Series E | 0 |
| 10/2009 | PrimeraDx (Primera Biosystems) | Series C | 20M |
| 10/2009 | Epizyme | Series B | 32M |
| 4/2014 | Iconic Therapeutics | Series B | 20M |
| 6/2012 | TriVascular | Series D | 60M |
| 3/2018 | TCR2 | Series B | 0 |
| 3/2010 | Rhythm Pharmaceuticals | Series A | 40M |
| 5/2003 | Accelerator Corp. | Venture Round | 0 |
| 7/2005 | Peptimmune | Series C | 20.4M |
| 10/2013 | Sideris Pharmaceuticals | Series A | 32M |
| 11/2010 | Aires Pharmaceuticals | Series B | 20M |
| 3/2009 | NeoVista | Series D | 18M |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 1/2016 | Iconic Therapeutics | Series C | 40M |
| 3/2021 | ElevateBio | Series C | 525M |
| 8/2016 | Iconic Therapeutics | Series C | 10M |
| 5/2023 | ElevateBio | Series D | 0 |
| 11/2006 | Orexigen Therapeutics, Inc. | Series C | 30M |
| 12/2011 | Aratana Therapeutics | Series B | 15M |
| 3/2007 | Theraclone Sciences | Series B | 29M |
| 8/2003 | Rinat Neuroscience | Series B | 40M |
| 9/2008 | Humanigen | Series D | 0 |
| 11/2019 | CODA Biotherapeutics | Series A | 15M |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 7/2011 | Nevro | Series B | 58M |
| 12/2011 | Radius Health | Private Equity Round | 21.4M |
| 11/2008 | Radius Health | Series C | 15M |
| 4/2007 | Xoft | Series D | 0 |
| 4/2007 | Syndax Pharmaceuticals | Series A | 40M |
| 3/2010 | Syndax Pharmaceuticals | Series A | 9M |
| 8/2013 | Syndax Pharmaceuticals | Series B | 0 |
| 5/2005 | Xoft | Series C | 0 |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 7/2005 | PrimeraDx (Primera Biosystems) | Series A | 11M |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 1/2016 | Tizona Therapeutics | Series A | 27M |
| 9/1999 | Pointshare | Series C | 40M |
| 11/2000 | Epigenomics | Venture Round | 24.1M |
| 7/2003 | Tercica | Series B | 44M |
| 5/2012 | Celladon | Venture Round | 10M |
| 5/2003 | BioXell | Series B | 19.9M |
| 10/2007 | Allozyne | Series B | 30M |
| 7/2013 | InformedDNA | Seed Round | 3M |
| 12/2005 | Allozyne | Series A | 3.5M |
| 3/2013 | Theraclone Sciences | Series B | 0 |
| 5/2009 | Elixir Pharmaceuticals | Series D | 12M |
| 3/2010 | Theraclone Sciences | Venture Round | 1.5M |
| 9/2012 | Selexys Pharmaceuticals Corporation | Series A | 23M |
| 10/2004 | MacroGenics | Series B | 30.5M |
| 3/2016 | Potenza Therapeutics | Venture Round | 30M |
| 9/2008 | ForteBio | Series C | 25M |
| 7/2003 | Intercell | Series C | 50M |
| 9/2010 | Motus Therapeutics | Series A | 19M |
| 10/2003 | AVEO Oncology | Series B | 42.7M |
| 2/2011 | NeoVista | Series E | 33M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 5/2002 | AVEO Oncology | Series A | 15M |
| 3/2003 | Peptimmune | Series B | 41.2M |
| 2/2017 | Rhythm Pharmaceuticals | Venture Round | 41M |
| 6/2006 | Peptimmune | Series C | 0 |
| 8/2015 | Rhythm Metabolic | Series A | 40M |
| 8/2010 | TriVascular | Series C | 60M |
| 11/2009 | TriVascular | Series B | 30M |
| 3/2013 | Nevro | Series C | 0 |
| 11/2009 | Oxagen | Series C | 0 |
| 5/2009 | Proteon Therapeutics | Series B | 50M |
| 10/2007 | Acceleron Pharma | Series C | 31M |
| 9/2012 | Vascular Pharmaceuticals | Series A | 16M |
| 4/2004 | Corus Pharma | Series C | 0 |
| 7/2015 | Blade Therapeutics | Series A | 6.5M |
| 5/2010 | Ntprx | Series B | 43M |
| 11/2010 | iPierian | Series B | 29M |
| 9/2013 | iPierian | Venture Round | 30M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 8/2019 | Oncorus | Series B | 0 |
| 6/2016 | Blade Therapeutics | Series B | 45M |
| 5/2014 | Proteon Therapeutics | Series D | 0 |
| 11/2013 | TriVascular | Series E | 0 |
| 11/2018 | Harpoon Therapeutics | Series C | 70M |
| 10/2004 | BioXell | Series C | 29M |
| 9/2016 | IOmx Therapeutics | Series A | 44.6M |
| 8/2000 | Syrrx | Series A | 5.1M |
| 8/2020 | Dyne Therapeutics | Series B | 115M |
| 1/2002 | CryoCor | Series B | 12M |
| 1/2005 | CHF Solutions | Venture Round | 22.9M |
| 1/2010 | Dragonfly Sciences | Venture Round | - |
| 2/2003 | Synergia Pharma | Series A | 2M |
| 3/2019 | TriNetX | Series D | 40M |
| 11/2009 | EndoGastric Solutions | Series E | 0 |
| 10/2009 | EndoGastric Solutions | Venture Round | 0 |
| 11/2006 | Solasia Pharma | Pre Seed Round | - |
| 5/2015 | Blade Therapeutics | Seed Round | - |
| 9/2018 | CODA Biotherapeutics | Series A | 19M |
| 6/2013 | Pierian Biosciences | Private Equity Round | 18M |
| 6/2002 | Cardiac Dimensions | Series B | 12M |
| 6/2007 | Athersys | Venture Round | 0 |
| 12/2006 | NeoVista | Series C | 41M |
| 8/2011 | Proteon Therapeutics | Series C | 15.2M |
| 1/2002 | Archus Orthopedics | Series A | - |
| 3/2003 | Hypnion | Series B | 47.5M |
| 1/2011 | Mitobridge | Seed Round | - |
| 3/2004 | Restore Medical | Series C | 26.5M |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 1/2021 | Werewolf Therapeutics | Series B | 0 |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 11/2008 | ARYx Therapeutics | Post-IPO Equity | 21.6M |
| 1/2012 | CoStim Pharmaceuticals | Seed Round | - |
| 12/2008 | Humanigen | Series D | 12M |
| 10/2004 | PharmAthene | Series B | 50M |
| 12/2019 | Triplet Therapeutics | Series A | 49M |
| 1/2008 | Peptimmune | Series D | 8.2M |
| 4/2004 | Affymax | Series C | 20M |
| 7/2007 | Xanodyne | Series A | 25M |
| 6/2014 | True North Therapeutics | Series A | 22M |
| 7/2014 | Cerecor | Series B | 32M |
| 5/2023 | ReNAgade Therapeutics | Series A | 0 |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 9/2022 | Photys Therapeutics | Series A | 0 |
| 8/2022 | Aktis Oncology | Series A | 0 |
| 8/2022 | Orna Therapeutics | Series B | 0 |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 10/2021 | Protego Biopharma | Series A | 0 |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
